Literature DB >> 11927940

Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor.

Olga V Volpert1, Tetiana Zaichuk, Wei Zhou, Frank Reiher, Thomas A Ferguson, P Michael Stuart, Mohammad Amin, Noel P Bouck.   

Abstract

Natural inhibitors of angiogenesis are able to block pathological neovascularization without harming the preexisting vasculature. Here we show that two such inhibitors, thrombospondin-1 and pigment epithelium-derived factor, derive specificity for remodeling vessels from their dependence on Fas/Fas ligand (FasL)-mediated apoptosis to block angiogenesis. Both inhibitors upregulated FasL on endothelial cells. Expression of the essential partner of FasL, Fas/CD95 receptor, was low on quiescent endothelial cells and vessels but greatly enhanced by inducers of angiogenesis, thereby specifically sensitizing the stimulated cells to apoptosis by inhibitor-generated FasL. The anti-angiogenic activity of thrombospondin-1 and pigment epithelium-derived factor both in vitro and in vivo was dependent on this dual induction of Fas and FasL and the resulting apoptosis. This example of cooperation between pro- and anti-angiogenic factors in the inhibition of angiogenesis provides one explanation for the ability of inhibitors to select remodeling capillaries for destruction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927940     DOI: 10.1038/nm0402-349

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  126 in total

1.  Transcription-controlled gene therapy against tumor angiogenesis.

Authors:  Shoshana Greenberger; Aviv Shaish; Nira Varda-Bloom; Keren Levanon; Eyal Breitbart; Iris Goldberg; Iris Barshack; Israel Hodish; Niva Yaacov; Livnat Bangio; Tanya Goncharov; David Wallach; Dror Harats
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

2.  Vasohibin: the feedback on a new inhibitor of angiogenesis.

Authors:  Robert S Kerbel
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

3.  Growth factors/chemokines in diabetic vitreous and aqueous alter the function of bone marrow-derived progenitor (CD34⁺) cells in humans.

Authors:  Sankarathi Balaiya; Maria B Grant; Joshua Priluck; Kakarla V Chalam
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-08-26       Impact factor: 4.310

Review 4.  Thrombospondins in the transition from myocardial infarction to heart failure.

Authors:  Jonathan A Kirk; Oscar H Cingolani
Journal:  J Mol Cell Cardiol       Date:  2015-12-10       Impact factor: 5.000

5.  Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism.

Authors:  Balveen Kaur; Sarah M Cork; Eric M Sandberg; Narra S Devi; Zhaobin Zhang; Philip A Klenotic; Maria Febbraio; Hyunsuk Shim; Hui Mao; Carol Tucker-Burden; Roy L Silverstein; Daniel J Brat; Jeffrey J Olson; Erwin G Van Meir
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 6.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

7.  Murine corneal transplantation: a model to study the most common form of solid organ transplantation.

Authors:  Xiao-Tang Yin; Deena A Tajfirouz; Patrick M Stuart
Journal:  J Vis Exp       Date:  2014-11-17       Impact factor: 1.355

8.  Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2007-11-07       Impact factor: 6.261

9.  Pigment-epithelium-derived factor (PEDF) occurs at a physiologically relevant concentration in human blood: purification and characterization.

Authors:  Steen V Petersen; Zuzana Valnickova; Jan J Enghild
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

Review 10.  Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments.

Authors:  Y Mirochnik; A Kwiatek; O V Volpert
Journal:  Curr Drug Targets       Date:  2008-10       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.